There are currently 462 clinical trials in Rochester, New York looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Rochester, University of Rochester Medical Center, James P. Wilmot Cancer Center at University of Rochester Medical Center and Rochester Clinical Research, Inc.. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age
NCT06546423
Recruiting
HPIV3 and HMPV are viruses that can cause breathing problems in children. The goal of this clinical trial is to look at the safety of 2 experimental HPIV3/HMPV vaccines in HPIV3-seropositive children ≥ 24 months to \< 60 months of age. Children will receive B/HPIV3/HMPV-PreF-A vaccine, B/HPIV3/HMPV-F-B365 vaccine, or placebo, and participants will not know which study product they have received. The main goals of the study are to find out whether these vaccines are well-tolerated and infectious... Read More
Gender:
ALL
Ages:
Between 24 months and 59 months
Trial Updated:
08/08/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Human Metapneumovirus, Human Parainfluenza Virus Type 3
Register for Updates
AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05916339
Recruiting
This study is a pragmatic clinical trial examining the comparative effectiveness of two stimulant medications (methylphenidate and amphetamine) in the treatment of ADHD in children and adolescents with autism. Using a sequential, multiple assignment randomization trial (SMART) design the study will not only assess these two medications but also the role of an increasingly popular class of ADHD medication, the alpha-2 agonists. Findings from this study will help improve clinicians' approach to me... Read More
Gender:
ALL
Ages:
Between 4 years and 17 years
Trial Updated:
08/07/2024
Locations: University of Rochester, Rochester, New York
Conditions: ADHD, Autism Spectrum Disorder
Register for Updates
ABTECT - Maintenance
NCT05535946
Recruiting
This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhi... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
08/06/2024
Locations: Rochester Clinical Research, Rochester, New York
Conditions: Ulcerative Colitis
Register for Updates
Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension
NCT06477640
Recruiting
The purpose of this study is to evaluate whether a home rehabilitation program for patients diagnosed with Pulmonary Arterial Hypertension (PAH) will decrease Cardiac Effort (number of heart beats used during 6-minute walk test/walk distance) and improve quality of life. Ultimately, this information could help improve the management of patients with PAH.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Pulmonary Arterial Hypertension PAH
Register for Updates
A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence
NCT04645810
Recruiting
The purpose of this study is to learn more about what effects the use of high-dose-rate (HDR) brachytherapy on prostate cancer recurrence, seen by AXUMIN PET scan, has on prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/03/2024
Locations: University of Rochester, Rochester, New York
Conditions: Prostate Cancer, HDR
Register for Updates
Efficacy of the Dreem 3S Ambulatory Sleep Monitoring Device for the Evaluation of Narcolepsy
NCT06531876
Recruiting
This study intends to examine the utility of a home-use EEG-based sleep monitor for the diagnosis and evaluation of disorders of excessive sleepiness, specifically the neurological disorder Narcolepsy Type 1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2024
Locations: Sleep Insights Medical Associates PLLC, Rochester, New York
Conditions: Narcolepsy Type 1, Hypersomnia, Sleep Disorder
Register for Updates
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
NCT05507203
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrin... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/25/2024
Locations: Rochester Clinical Research, Rochester, New York
Conditions: Ulcerative Colitis
Register for Updates
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT04278768
Recruiting
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS). Patients enrolling in the Phase 1 dose escalation of the study must meet one of the following criteria prior to consenting to the study: * Relapse/refractory (R/R) AML with FMS-like tyrosine kinase-3 (FLT3) mutations who have been previously treated with a FLT3 inhibitor * R/R AML... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Register for Updates
Regeneron AA Multicenter (Dupilumab)
NCT05551793
Recruiting
This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affecting more than 50% of the scalp) at the time of screening with a targeted 54 subjects completers through Week 48. AA subjects must have evidence of hair regrowth within the last 7 years of their last episode of hair loss; and have screening IgE ≥ 200 and/or have personal and/or familial history of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: UR Dermatology at College Town, Rochester, New York
Conditions: Alopecia Areata
Register for Updates
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
NCT04731844
Recruiting
To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2024
Locations: University of Rochester, Rochester, New York
Conditions: Prostate Cancer, Multiple Myeloma, Smoldering Multiple Myeloma (SMM), Monoclonal Gammopathy of Undetermined Significance
Register for Updates
Study of ALTO-300 in MDD
NCT05922878
Recruiting
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/05/2024
Locations: Site 191, Rochester, New York
Conditions: Major Depressive Disorder
Register for Updates
Longitudinal Endpoint Assessment of Disease Burden in HD
NCT06475898
Recruiting
LEAD-HD is intended to collect and analyze self-reported health information from individuals with Huntington Disease (HD) or prodromal HD participating in a 24-month longitudinal natural history study using remote technologies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2024
Locations: Huntington Study Group, Rochester, New York
Conditions: Huntington Disease
Register for Updates